invest summari reiter ow rate increas
month price target share post ep beat
ahead expect strong year oper compani given
durabl busi model think multipl hold upward earn
revis drive share higher think multipl support
diversifi busi model solid execut upward earn revis could
come higher-than-anticip peak sale new launch better-than-
expect oper margin improv
posit quarter support thesi revenu grew
oper basi includ abaxi acquisit companion anim
growth oper basi driven sale legaci abaxi
product key dermatolog product parasiticid livestock grew
oper basi primarili driven poultri although speci contribut
growth despit impact asf juli receiv posit opinion
european medicin agenc cvmp three-way combin
parasiticid dog look forward final decis ec later
year regulatori review also underway canada australia
brazil japan submiss expect china mexico
year approv anticip product come market europ
 recent gain approv proheart
industri once-yearli inject prevent heartworm diseas dog
recent announc plan acquir platinum perform privat
held nutrition-focus anim heath compani acquisit expect
complet expect apoquel cytopoint sale
yoy sg growth moder due anniversari
abaxi deal yoy growth slow due anniversari
abaxi deal expect industri grow
companion anim growth livestock less asf
impact increas expect worsen
gross margin moder
report ep factset consensu
higher estim increas ep guidanc
factset consensu updat financi
model increas ep estim
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk posit invest thesi price target
restrict ban use antibacteri food-produc anim may
becom preval zoeti current sell antibacteri product govern
consum begun shift away consum prefer and/or govern
regul grow may affect zoetiss abil meet forecast
advers weather condit avail natur resourc could drive
price feed expens compon produc feed price rise
profit fall zoetiss custom may spend less anim health drug
lack new product launch and/or exist product fail gain market share
street good expect zoetiss new launch compani perform
line better expect could downsid risk number
macro factor weather feed price currenc could advers impact sale
earn zoeti off-set sinc global busi said macro factor
global could pressur earn
oper margin expans lower expect zoeti still gross margin
expans expect compani meet target and/or
margin improv seen to-dat sustain could downsid number
brand and/or gener competit key drug zoeti face competit could
headwind sale given larg number product portfolio compani
strong relationship custom see smaller type risk
bull bear base case analysi
use dcf multipl price-to-earnings analysi arriv bull bear case scenario
base analysi estim likelihood stock worth next
exhibit bull bear base case scenario analysi
amount chang yoyamount chang total driven primarili companion anim abaxi dermatolog parasiticid in-lin driven foreign exchang impact price product mix unit cost improv gross oper oper non oper pre-tax tax net averag cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom acquisit platinum performancesept-oct trioapprov trioregulatori submiss china mexicobi end animallarg complet expans field driver launch season simparica triolaunch place one global version sap custom agreement pfeexpir may may increas manufactur network vs strategycomplet step two focus excel mab candidateu /eu approv control pain associ w/ osteoarthr launch cat new mab candidatelaunch chronic pain patent set vaccineslaunch patent set strategycomplet step three invest growthsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
zoeti anim health compani focus discoveri develop manufactur commerci anim health medicin
diagnost vaccin across livestock companion anim zoeti focus eight core speci cattl swine poultri sheep
fish form part compani livestock segment dog cat hors manag compani companion anim
segment zoetiss five major product categori within segment anti-infect vaccin parasiticid medic feed addit
pharmaceut
